ALFA Finder| Revenue growth | 11.6% YoY consolidated; 7% YoY standalone. |
|---|---|
| Margins | Consolidated EBITDA margin 14.5% vs 16.0% YoY; Standalone 18.4% vs 21.6% YoY. |
| Demand visibility | Strong, driven by surgery volumes and international patient growth (42% in international). |
| Management confidence | High; emphasizing global leadership in joint replacement. |
Growth
Consolidated revenue grew 11.6% YoY; EBITDA grew 0.9% to ₹490 mn. Standalone revenue grew 7.0% YoY to ₹2,591 mn.
Outlook
Targeting 40% additional bed capacity for organic growth; expansion plan focused on Mumbai hospitals; doubling ROCE via operational leverage.
Risks
EBITDA margins compressed YoY from 16.0% to 14.5% consolidated and 21.6% to 18.4% standalone.
Last quarter's promises, checked
Delivered
- Guided MedTech EBITDA turnaround → delivered ₹3.7 cr (= BEAT)
- Targeted new tax regime benefit → delivered 25% vs 35% rate (= BEAT)
- Guided International patient recovery → delivered 42% growth (= BEAT)
Partly delivered
- Targeted 15% sustainable CAGR → delivered 11.6% revenue growth (= PARTIAL)
- Guided occupancy north of 50% → delivered 48% (50% excl. Gurugram) (= PARTIAL)
Missed
- Guided gross margin maintenance → delivered 85% vs 90% (= MISS)
- Targeted consolidated EBITDA growth → delivered 0.9% vs 43.1% prev (= MISS)
- Guided ARPOB growth → delivered -2.1% YoY (= MISS)
Investor Presentation filed with NSE, NSE: SHALBY. Summary written with AI assistance from the document.
Shalby Ltd: key numbers
- Share price
- ₹126.99
- Market cap
- ₹1,372 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 35.0×Sector 54.5×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Other Announcement
Shalby Limited disclosed under Regulation 30(5) that the board authorised KMP personnel for materiality determination. Mr. Tushar Shah's designation was revised after his appointment as Executive Director.
Shalby Earnings Call Transcript: Key Takeaways
Consolidated revenue rose 9.8%, but EBITDA grew only 0.8% and margin fell 130 bps to 14.6%. PAT was flat at ₹7.9 Cr. Standalone hospitals carry profit while subsidiaries drag. Management deflected on Mumbai, MedTech expansion and POSO revenue.
Shalby Investor Presentation: Key Takeaways
Consolidated Q2 FY27 revenue ₹3,182mn (+9.8% YoY), EBITDA flat at ₹464mn, margin 14.6%, PAT ₹79mn (+8.3%). Standalone PAT +19%; growth driven by International and occupancy.
Shalby Annual General Meeting
Shalby Ltd seeks shareholder approval via postal ballot to appoint Shanay Vikram Shah and Tushar Shah as directors. E-voting runs November 5 to December 4, 2026.
Shalby Management Change
Shalby Limited appointed Mr. Tushar Shah as Executive Director for five years, effective November 3, 2026, subject to shareholder approval. The change is a senior management appointment.
- Execution
- 5 years from November 3, 2026
Shalby Q2 FY27 Results: Net Profit ₹7.9 Cr, Up 8.2% YoY
Shalby Ltd reported revenue from operations of ₹313.2 Cr (+9.7% YoY) and net profit of ₹7.9 Cr (+8.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.9 Cr · +8.2% YoY